Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Piromelatine - Neurim Pharmaceuticals

Alternative Names: Neu-P11

Latest Information Update: 22 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurim Pharmaceuticals
  • Class Antidementias; Sleep disorder therapies; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Melatonin receptor agonists; Serotonin 1D receptor agonists; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Insomnia
  • No development reported Metabolic syndrome; Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 12 May 2022 Phase-II/III clinical trials in Alzheimer's disease (In the elderly, In adults) in USA (PO) (NCT05267535)
  • 04 Mar 2022 Neurim Pharmaceuticals plans a phase II/III trial for Alzheimer's Disease (In adults, In the elderly) in May 2022 (PO, Tablet) (NCT05267535)
  • 08 Sep 2021 Piromelatine is still in phase II trials in Alzheimer's disease (In adults, In the elderly) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now